{"product_id":"global-nuclear-medicine-radiopharmaceuticals-market-growth-2023-2029","title":"Global Nuclear Medicine \u0026 Radiopharmaceuticals Market Growth 2023-2029","description":"\u003cp\u003eGlobal Nuclear Medicine \u0026amp; Radiopharmaceuticals Market Growth 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eRadiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.\u003cbr\u003e\nLPI (LP Information)' newest research report, the “Nuclear Medicine \u0026amp; Radiopharmaceuticals Industry Forecast” looks at past sales and reviews total world Nuclear Medicine \u0026amp; Radiopharmaceuticals sales in 2022, providing a comprehensive analysis by region and market sector of projected Nuclear Medicine \u0026amp; Radiopharmaceuticals sales for 2023 through 2029. With Nuclear Medicine \u0026amp; Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nuclear Medicine \u0026amp; Radiopharmaceuticals industry.\u003cbr\u003e\nThis Insight Report provides a comprehensive analysis of the global Nuclear Medicine \u0026amp; Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Nuclear Medicine \u0026amp; Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nuclear Medicine \u0026amp; Radiopharmaceuticals market.\u003cbr\u003e\nThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nuclear Medicine \u0026amp; Radiopharmaceuticals and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nuclear Medicine \u0026amp; Radiopharmaceuticals.\u003cbr\u003e\nThe global Nuclear Medicine \u0026amp; Radiopharmaceuticals market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003cbr\u003e\nThe major players in Chian Nuclear Medicine \u0026amp; Radiopharmaceuticals market include China Isotope \u0026amp; Radiation, Shanghai Atom Kexing, Advanced Molecular-imaging Solution, etc. Beijing and Chengdu are main markets, they occupy about 65% of the whole market. Diagnostic is the main type, with a share about 80%. Cardiology is the main application, which holds a share about 40%.\u003cbr\u003e\nThis report presents a comprehensive overview, market shares, and growth opportunities of Nuclear Medicine \u0026amp; Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.\u003cbr\u003e\nMarket Segmentation:\u003cbr\u003e\nSegmentation by type\u003cbr\u003e\n Diagnostic\u003cbr\u003e\n Therapeutic\u003cbr\u003e\nSegmentation by application\u003cbr\u003e\n Oncology\u003cbr\u003e\n Thyroid\u003cbr\u003e\n Cardiology\u003cbr\u003e\n Others\u003cbr\u003e\nThis report also splits the market by region:\u003cbr\u003e\n Americas\u003cbr\u003e\n United States\u003cbr\u003e\n Canada\u003cbr\u003e\n Mexico\u003cbr\u003e\n Brazil\u003cbr\u003e\n APAC\u003cbr\u003e\n China\u003cbr\u003e\n Japan\u003cbr\u003e\n Korea\u003cbr\u003e\n Southeast Asia\u003cbr\u003e\n India\u003cbr\u003e\n Australia\u003cbr\u003e\n Europe\u003cbr\u003e\n Germany\u003cbr\u003e\n France\u003cbr\u003e\n UK\u003cbr\u003e\n Italy\u003cbr\u003e\n Russia\u003cbr\u003e\n Middle East \u0026amp; Africa\u003cbr\u003e\n Egypt\u003cbr\u003e\n South Africa\u003cbr\u003e\n Israel\u003cbr\u003e\n Turkey\u003cbr\u003e\n GCC Countries\u003cbr\u003e\nThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\n China Isotope \u0026amp; Radiation\u003cbr\u003e\n Dongcheng\u003cbr\u003e\n Jaco\u003cbr\u003e\n Ciaeriar\u003cbr\u003e\n Advanced Molecular-imaging Solution\u003cbr\u003e\n Shanghai Atom Kexing\u003cbr\u003e\nKey Questions Addressed in this Report\u003cbr\u003e\nWhat is the 10-year outlook for the global Nuclear Medicine \u0026amp; Radiopharmaceuticals market?\u003cbr\u003e\nWhat factors are driving Nuclear Medicine \u0026amp; Radiopharmaceuticals market growth, globally and by region?\u003cbr\u003e\nWhich technologies are poised for the fastest growth by market and region?\u003cbr\u003e\nHow do Nuclear Medicine \u0026amp; Radiopharmaceuticals market opportunities vary by end market size?\u003cbr\u003e\nHow does Nuclear Medicine \u0026amp; Radiopharmaceuticals break out type, application?\u003cbr\u003e\nWhat are the influences of COVID-19 and Russia-Ukraine war?\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 95 Pages \/ MCW16234633","offer_id":47650991440178,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-nuclear-medicine-radiopharmaceuticals-market-growth-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}